On the other hand, pharmacological inhibition of CCL2 accelerated fibrosis resolution in mouse models of liver fibrosis [65], thereby supporting the development of drugs targeting CCL2 receptors for NASH therapy [66]. Here, CCL2 is linked to Hepatic fibrosis.